Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-006: MK-7684A + cCRT vs Durvalumab + cCRT in Unresectable Stage III NSCLC
NCT05298423Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of vibostolimab + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started May 2022; status: completed.
02
Drugs
vibostolimab + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05298423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298423.